-
There is no difference in rates of treatment failure, death, or readmission for COPD between patients treated with oral or intravenous steroids for exacerbation of COPD, but the IV route may be associated with increased cost and length of stay.
-
The first receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor has been approved for the treatment of osteoporosis.
-
Fibrates: Generally safe, but do they improve outcomes? According to this meta-analysis, the answer to the question above very much depends upon which outcome you believe is important.
-
Get ready to add another option to the list of emergency contraception (EC) methods. The Food and Drug Administration has approved ella (ulipristal acetate, UPA) tablets.
-
While vaginitis usually is considered a minor nuisance, many women experience chronic symptoms that persist or recur after treatment. What can clinicians do?
-
Good news! Scientists have discovered two potent human antibodies that can neutralize more than 90% of known global HIV strains from infecting human cells in the laboratory, and they have demonstrated how one of these disease-fighting proteins achieves this action.
-
Your next patient is a recently divorced 48-year-old mother of two. Her menstrual periods have become somewhat irregular, and she reports occasional hot flashes and night sweats.
-
The search for a female-controlled form of HIV prevention just took a giant step. Results of a Phase IIB trial of a tenofovir gel indicate that use of the gel before and after sex provided moderate protection against sexually transmitted HIV.
-
Male pattern baldness treated with oral dutasteride; Home-based diagnosis of sleep apnea; What is the risk of bariatric surgery?; Comparing insulin and incretins; Which is better: COX2 or NSAID plus PPI?; Combination therapy to prevent DM2
-
A recent report described a fatal case of community-acquired C. difficile diarrhea (CDAD) in a patient receiving antibiotics for a questionable diagnosis of chronic Lyme disease.
